by Maria Zannes | Sep 23, 2021 | Press Releases
Australian Patent Office Issues Notice of Acceptance for Patent Related to Porphyrin Compounds and Compositions to Treat Cancer SEPTEMBER 23, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company, announced that the Australian Patent Office...
by Maria Zannes | Sep 16, 2021 | News
Alamo City company has reached critical milestone that could lead to more commercial opportunities SEPTEMBER 16, 2021 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San-Antonio Business Journal More than seven years after its...
by Maria Zannes | Sep 14, 2021 | Press Releases
CyPath® Lung, an Innovative Lung Cancer Diagnostic, Fully Validated as a Laboratory Developed Test (LDT) by CAP/CLIA-Certified Laboratory SEPTEMBER 9, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company advancing innovative cancer...
by Maria Zannes | Sep 10, 2021 | Events
bioAffinity Technologies President and CEO Maria Zannes will present the Company’s recent advancements in commercializing CyPath® Lung, a noninvasive test to diagnose early stage lung cancer and meet with investors at H.C. Wainwright & Company’s 23rd Annual Global...
by Maria Zannes | Aug 12, 2021 | Press Releases
AUGUST 12, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced publication in the peer-reviewed Journal of Visualized Experiments (JoVE). The paper, entitled Quality-Controlled...
